PBE vs XBI

PBEBInvesco Biotechnology & Genome ETF

XBIAState Street SPDR S&P Biotech ETF

In short

PBE Most biotech funds own the sector by size. PBE has run a different playbook since 2005: a quant screen on momentum, quality and value that narrows the field to roughly 30 names, reshuffled every quarter.

XBI Biotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.

Stated mandate

PBE The Fund seeks to track, before fees and expenses, the results of its designated biotechnology and genome benchmark index.

XBI The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.

Why people hold it

• PBE The index scores biotech and genome companies on price momentum, earnings momentum, quality, management action and value, then reconstitutes quarterly, so the roster follows the scores.pionline.com
• Trading since 2005, one of the longest-running biotech ETFs on the tape, and it has stayed tight to the index it promises to follow.
• About 30 holdings, so an approval or a trial readout at one company registers in the portfolio instead of being diluted across a sprawling roster.
• Sits in the upper half of the biotech and genomics group on our review, with no structural red flags in the wrapper and a plain index mandate on file with the SEC.sec.gov

• XBI Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
• 0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
• Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
• A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.

Worth knowing

• PBE 0.59% sits above the category median, and above plain index rivals like IBB at 0.44% and XBI at 0.35%. The screening model is what you pay the difference for.
• Thinly traded next to the category's heavyweights, so spreads can be wider and bigger orders need more care at the point of execution.
• A 30-stock quant portfolio can diverge sharply from the broad biotech benchmark in either direction, and it pays out only quarterly.

• XBI Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.comnasdaqomx.com
• Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
• One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com

Full PBE profile⁠

Full XBI profile⁠